Lapuleucel-T

Autologous active cellular immunotherapy with lapuleucel-T was feasible, safe, and well tolerated. The treatment stimulated significant immune responses, which were enhanced after boost infusions

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jones, Lori A: 2 articles (09/2009 - 08/2007)
2.	Melisko, Michelle E: 2 articles (09/2009 - 08/2007)
3.	Park, John W: 2 articles (09/2009 - 08/2007)
4.	Alberts, Steven R: 1 article (09/2009)
5.	Frohlich, Mark W: 1 article (09/2009)
6.	Lin, Lisa R C: 1 article (09/2009)
7.	Peethambaram, Prema P: 1 article (09/2009)
8.	Provost, Nicole M: 1 article (09/2009)
9.	Rinn, Kristine J: 1 article (09/2009)
10.	Sims, Robert B: 1 article (09/2009)

Related Diseases

1.	Neoplasms (Cancer) 09/15/2009 - "This study aimed to evaluate the safety of, immune response induced by, and efficacy of treatment with lapuleucel-T (APC8024) in patients with HER-2/neu-expressing tumors. " 09/15/2009 - "A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu." 08/20/2007 - "Lapuleucel-T therapy was associated with tumor response or extended disease stabilization in some patients and warrants further investigation."
2.	Breast Neoplasms (Breast Cancer) 08/20/2007 - "We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer. " 08/20/2007 - "Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer."
3.	Influenza in Birds (Avian Flu) 06/01/2008 - "(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine, Denosumab, Desloratadine, DMXB-Anabaseine, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Eicosapentaenoic acid/docosahexaenoic acid, Eletriptan, Enzastaurin hydrochloride, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumarate, Fulvestrant; Gefitinib, GM-CSF DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human Fibroblast Growth Factor 1, Hypericin-PVP; Icatibant acetate, Iclaprim, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-IL-2, Lapuleucel-T, Laropiprant, Liposomal doxorubicin, LP-261, Lumiracoxib, LY-518674; MDV-3100, MGCD-0103, Mirabegron, MyoCell; NASHA/Dx, Niacin/laropiprant; O6-Benzylguanine, Ocrelizumab, Olmesartan medoxomil, Omalizumab; P-276-00, Paclitaxel nanoparticles, Paclitaxel nanoparticles, Padoporfin, Paliperidone, PAN-811, Pegaptanib octasodium, Pegfilgrastim, Pemetrexed disodium, PF-00299804, Pimecrolimus, Prasugrel, Pregabalin; Reolysin, Rimonabant, Rivaroxaban, Rosuvastatin calcium; Satraplatin, SCH-697243,Selenite sodium, Silodosin, Sorafenib, Sunitinib malate; Talarozole, Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; Xience V; Zotarolimus-eluting stent."

Related Drugs and Biologics

1.	Autoantigens
2.	Antigens
3.	Ferrosoferric Oxide (Magnetite)
4.	Simvastatin (Zocor)
5.	Hepatitis B Vaccines (Hepatitis B Vaccine)
6.	Amlodipine (Norvasc)
7.	Etodolac (Lodine)
8.	Paclitaxel (Taxol)
9.	Intravenous Immunoglobulins (IVIG)
10.	Fibroblast Growth Factor 1 (FGF-1)

Related Therapies and Procedures

1.	Immunotherapy
2.	Stents
3.	Therapeutics